



Sunday 29 June 2014

09:00-17:00	Satellite meeting COHRED: Sustainable investment in research for health	Salon 3-4
16:00-18:00	Registration	Foyer, Conference centre

Monday 30 June 2014

08:00-09:00	Registration	Foyer, Conference centre
09:00-10:30	Plenary session I Forum prologue	Hall I B-C
	Chairs: Beate Kampmann and John Gyapong Rapporteur: Karin Fischer-Buder	
09:00-09:10	Dr Renate Loskill , Head of Department for Health Research, Federal Ministry for Education and Research, Germany <i>Welcome address</i>	
09:10-09:25	Prof. Stefano Vella and Dr Detlef Böcking , Vice-Chairs EDCTP General Assembly <i>Towards EDCTP2</i>	
09:25-09:40	Prof. Francine Ntoumi , Member of the EDCTP Association Board <i>The evolution of EDCTP governance</i>	
09:40-10:00	Dr Line Matthiessen , DG Research and Innovation, European Commission <i>European Commission perspective on the EDCTP programme</i>	
10:00-10:30	Prof. Charles Mgone , EDCTP Executive Director <i>Introduction of the Forum theme</i>	
10:30-11:00	Coffee and tea break	Hall II
10:30-11:00	Marketplace views	Hall II
11:00-12:30	Plenary session II Recent advances in HIV/AIDS, tuberculosis and malaria (keynote addresses) Chairs: Marie-Louise Newell and Tumani Corrah Rapporteur: Karin Fischer-Buder	Hall I B-C
11:00-11:30	HIV/AIDS: Gita Ramjee , Medical Research Council, South Africa	PS.01
11:30-12:00	Malaria: Pedro Alonso , CRESIB, Spain	PS.02
12:00-12:30	Tuberculosis: Ann Ginsberg , Aeras, United States of America	PS.03
12:30-13:30	Lunch	Hall II
12:30-13:30	Marketplace views	Hall II

Monday 30 June 2014

13:30-15:30	Plenary session III Recent advances in neglected infectious diseases, health services optimisation research (keynote addresses) and update on Horizon 2020	Hall I B-C
	Chairs: Moses Bockarie and Knut Fylkesnes Rapporteur: Karin Fischer-Buder	
13:30-14:00	Neglected infectious diseases: John Gyapong , University of Ghana	PS.04
14:00-14:30	Health services optimisation research: Shabbar Jaffar , London School of Hygiene and Tropical Medicine, United Kingdom	PS.05
14:30-15:30	Horizon 2020: Line Matthiessen , DG Research and Innovation, European Commission	
15:30-16:00	Coffee and tea break	Hall II
15:30-16:00	Marketplace views	Hall II
16:00-17:00	Parallel session HIV/AIDS immunology and vaccine development	Hall I B-C
	Chairs: Pontiano Kaleebu and Souleymane Mboup Rapporteurs: Photini Kiepiela and Monique Surette	
16:00-16:20	Tomáš Hanke , University of Oxford, United Kingdom <i>Targeting HIV-1 by vaccines at conserved regions</i>	HO.01
16:20-16:40	Keabetswe Bedi , University of Botswana/BHP, Botswana <i>Evolution of neutralising antibodies in acute heterosexually acquired HIV-1 subtype C infection in Botswana</i>	HO.02
16:40-17:00	Moustapha Mbow , CHU Le Dantec, Senegal <i>Natural killer cells of HIV-1-exposed but uninfected subjects exhibit recall responsiveness to HIV-1 peptides</i>	HO.03
16:00-17:00	Parallel session Tuberculosis therapeutic studies	Salon 2
	Chairs: Ali Zumla and Suzanne Verver Rapporteurs: Lyn Horn and Nesri Padayatchi	
16:00-16:20	Martin Boeree , Radboud University Nijmegen, The Netherlands <i>What is the "right" dose of rifampin?</i>	TO.01
16:20-16:40	Amina Jindani , St. George's, University of London, United Kingdom <i>High dose rifapentine with a quinolone for treatment of pulmonary tuberculosis: the RIFAQUIN trial</i>	TO.02
16:40-17:00	Eleni Aklillu , KI, Sweden <i>Optimisation of TB-HIV co-treatment in sub-Saharan Africa: no need to increase efavirenz dose during concomitant rifampicin-based antituberculosis therapy in HIV patients</i>	TO.03
16:00-17:00	Parallel session Malaria vaccine studies	Hall I A
	Chairs: Philippe Deloron and Francine Ntoumi Rapporteurs: Bourema Kouriba and Jean-Marie Habarugira	

Monday 30 June 2014

16:00-16:20	Michael Theisen , SSI, Denmark and Benjamin Mordmüller , ITM Tübingen, Germany <i>Phase IIb efficacy trial of the malaria blood stage vaccine candidate GMZ2</i>	MO.01
16:20-16:40	Seif Shekelaqhe , IHI, Tanza <i>Speeding up the development of malaria vaccines: the example of P27A, bridging phase Ia and Ib</i>	MO.02
16:40-17:00	Bernhards Ogutu , KEMRI-Walter Reed, Kenya <i>Controlled human malaria infections and irradiated whole sporozoite vaccine evaluation in Africa</i>	MO.03
16:00-17:00	Parallel session Cross-cutting: policy, ethics, regulatory and trials registration activities	Salon 3-4
	Chairs: Maria Fraga Oliveira Martins and Abraham Aseffa Rapporteurs: Nuraan Fakier and Elizabeth Pienaar	
16:00-16:20	Elizabeth Pienaar , MRC, South Africa <i>The Pan African Clinical Trials Registry (PACTR) five years later: where are we now?</i>	CO.01
16:20-16:40	Boitumelo Mokagla-Moipolai , COHRED, Botswana <i>Mapping African research ethics review and medicines regulatory capacity: the MARC project</i>	CO.02
16:40-17:00	Carel Ijsselmuiden , COHRED, Switzerland <i>The 'Research for Health and Innovation Organiser (RHINNO)' for ethics review</i>	CO.03
17:00-18:00	Marketplace views	Hall II
17:00-18:30	Special session EDCTP2 fellowship schemes	Salon 2
	Facilitators: Thomas Nyirenda and Gabrielle Breugelmans	
17:00-18:30	Satellite meeting DNDi: Combatting neglected tropical diseases: the case of visceral leishmaniasis in Africa	Salon 7
19:00-20:30	Conference dinner	

Tuesday 1 July 2014

08:00-09:00	Registration	Foyer, Conference centre
08:00-08:50	Special session EDCTP fellowship alumni	Salon 2
Facilitators: Thomas Nyirenda and Pauline Beattie		
08:00-08:50	Satellite meeting Discussion to explore ways to support clinical trials for malaria and neglected tropical diseases <i>By invitation only</i>	Salon 3-4
09:00-11:00	Parallel session HIV/AIDS therapeutic and prevention studies	Hall I B-C
Chairs: Gita Ramjee and Marie-Louise Newell Rapporteurs: Photini Kiepiela and Jonathan Kayondo		
09:00-09:20	Laura Ciaffi , University of Montpellier 1 (IRD 233), France <i>Randomised comparison of three second line ART regimens in Africa: the 2Lady/ANRS/EDCTP study</i>	HO.04
09:20-09:40	Cissy Kityo , JCRC, Uganda <i>HIV drug resistance in paediatric patients initiating antiretroviral therapy in Uganda: a multicentre observational study</i>	HO.05
09:40-10:00	Frank Angira , KEMRI-CDC, Kenya <i>Post-antiretroviral outcomes in a cohort of women who discontinued maternal triple-antiretrovirals initially used to prevent mother-to-child transmission of HIV during pregnancy</i>	HO.06
10:00-10:20	Richard Lando , KEMRI-CDC, Kenya <i>Adverse foetal outcomes in HIV-1 infected women who received either NNRTI or PI-based therapy for prevention of mother-to-child transmission of HIV in Western Kenya</i>	HO.07
10:20-10:40	Collen Masimirembwa , AiBST, Zimbabwe <i>Evaluation of genetic variants of drug metabolising enzymes and drug transporters as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort</i>	HO.08
10:40-11:00	Simani Gaseitsiwe , BHP, Botswana <i>High K65R levels in HIV-1 subtype C-infected patients failing a tenofovir-based first-line combination antiretroviral therapy regimen in Botswana</i>	HO.09
09:00-11:00	Parallel session Tuberculosis therapeutic studies	Salon 2
Chairs: Maryline Bonnet and Eleni Aklillu Rapporteurs: Lyn Horn and Jean Nachega		
09:00-09:20	Michael Hoelscher , University of Munich (LMU), Germany <i>Challenges of and perspectives on development and evaluations of new tuberculosis drug regimens</i>	TO.04
09:20-09:40	Norbert Heinrich , University of Munich (LMU), Germany <i>Results for SQ109, a new antituberculosis drug candidate, from a fourteen-day early bactericidal activity study</i>	TO.05

09:40-10:00	Charles Mtabho , KCRI, Tanzania <i>The effect of diabetes mellitus on the pharmacokinetics of tuberculosis drugs in Tanzanian patients</i>	TO.06
10:00-10:20	Yolandy Lemmer , CSIR, South Africa <i>Providing an address for delivery of nanoencapsulated tuberculosis drugs</i>	TO.07
10:20-10:40	Prisca Rabuogi , KEMRI/CDC, Kenya Evaluation of tuberculosis treatment outcomes in an infant tuberculosis incidence study in western Kenya	TO.08
10:40-11:00	Q&A session	
09:00-11:00	Parallel session Malaria therapeutic studies	Hall I A
Chairs: Philippe Deloron and Kalifa Bojang Rapporteurs: Charles Obonyo and Montserrat Blázquez Domingo		
09:00-09:20	Peter G. Kremsner , ITM Tübingen, Germany <i>A simplified artesunate regimen for severe malaria in children</i>	MO.04
09:20-09:40	Abdoulaye Djimdé , MRTC, University of Bamako, Mali <i>Safety of artesunate-pyronaridine in the repetitive treatment of uncomplicated malaria in sub-Saharan Africa</i>	MO.05
09:40-10:00	Issaka Zongo , IRSS, Burkina Faso <i>Efficacy of dihydroartemisinin-piperaquine in the treatment of uncomplicated P. falciparum malaria in African patients and day 7 plasma piperaquine concentration</i>	MO.06
10:00-10:20	Sidikiba Sidibe , CNFRSR, Guinea <i>Therapeutic efficacy of artesunate-amodiaquine combination in the treatment of uncomplicated malaria at Mafèrinyah, Republic of Guinea</i>	MO.07
10:20-10:40	Sodiomon Sirima and Alfred B. Tiono , CNRFP, Burkina Faso <i>Impact of community screening and treatment of asymptomatic carriers of Plasmodium falciparum with artemether-lumefantrine on asymptomatic and gametocyte carriage: a 12-month, cluster-randomised study</i>	MO.08
10:40-11:00	Alfred B. Tiono , CNRFP, Burkina Faso <i>Treatment of asymptomatic carriers of Plasmodium falciparum with artemether-lumefantrine: impact on the prevalence of anaemia</i>	MO.09
09:00-11:00	Parallel session Cross-cutting: planning, implementation and impact evaluation of clinical trials	Salon 3-4
Chairs: Knut Fylkesnes and Wilfred Mbacham Rapporteurs: Godwin Nchinda and Lucinda Manda-Taylor		
09:00-09:20	Maxime K. Drabo , IRSS/Centre Muraz, Burkina Faso <i>Impact of clinical trials on the quality of health care services in Burkina Faso: perception of community and health staff in Nanoro and Dafra districts</i>	CO.04
09:20-09:40	Elisabeth Stantley-Batchilly , MRC, The Gambia <i>Factors influencing the recruitment of participants for randomised clinical trials in Africa: an observational study in The Gambia</i>	CO.05
09:40-10:00	Elizabeth Ayuo , KEMRI-CDC, Kenya <i>A pragmatic and innovative strategy to improve quality of clinical trials in East Africa: update from the reciprocal monitoring scheme</i>	CO.06

10:00-10:20	Daniel Bauer , University of Munich (LMU), Germany <i>Monitoring and evaluation of health research capacity development activities: development of tools and instruments using the example of the Fozivudine in Africa Trials Initiative</i>	CO.07
10:20-10:40	Ghiorghis Belai , Family Health International, Kenya <i>Implementation challenges of the WANECAM study: a monitor's perspective</i>	CO.08
10:40-11:00	Q&A session	
11:00-11:30	Coffee and tea break	Hall II
11:00-11:30	Marketplace views	Hall II
11:30-13:00	Parallel session HIV/AIDS therapeutic studies	Hall I B-C
	Chairs: Shabbar Jaffar and Maria Fraga Oliveira Martins Rapporteurs: Photini Kiepiela and Jonathan Kayondo	
11:30-11:45	Divine Avit Edi , PAC-CI, Site ANRS, projet Monod, Côte d'Ivoire <i>Access to early infant diagnosis and antiretroviral therapy: barriers and challenges in Abidjan, Côte d'Ivoire in 2011-2013</i>	HO.10
11:45-12:00	Nicholas Paton , National University of Singapore, Singapore <i>A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the EARNEST trial</i>	HO.11
12:00-12:15	Nogbou Frédéric Ello , CHUT, Côte d'Ivoire <i>The Fozivudine in Africa Trials Initiative: first results from the FATI-1 phase II trial conducted in Mbeya, Tanzania and Abidjan, Côte d'Ivoire</i>	HO.12
12:15-12:30	Catherine Orrell , University of Cape Town, South Africa <i>A randomised trial to explore adherence-failure relationships in a South African antiretroviral cohort: baseline data analysis</i>	HO.13
12:30-12:45	Graeme Meintjes , University of Cape Town, South Africa <i>Efficacy of third line ART in Africa: outcomes on ART salvage regimens in the Southern African private sector</i>	HO.14
12:45-13:00	Kamija Phiri , University of Malawi <i>Benefits and risks of iron supplementation in HIV-infected Malawian children: results of a double-blind, randomised controlled trial</i>	HO.15
11:30-13:00	Parallel session Tuberculosis immunology and vaccine development	Salon 2
	Chairs: Beate Kampmann and Martin Ota Rapporteurs: Monique Surette and Jean-Marie Habarugira	
11:30-11:50	Ingrid Kromann , SSI, Denmark <i>Clinical development of tuberculosis subunit vaccine H1IC</i>	TO.09
11:50-12:10	Michele Tameris , SATVI, South Africa <i>Phase II safety and immunogenicity study of Aeras-402 in BCG-vaccinated, HIV-uninfected infants</i>	TO.10

12:10-12:30	Birahim P. Ndiaye , Laboratoire de Bactériologie et Virologie, Senegal. Incidence of tuberculosis among a cohort of HIV positive adults enrolled in a TB vaccine clinical trial in Senegal	TO.11
12:30-12:50	Novel N. Chegou , Stellenbosch University, South Africa <i>Utility of Mycobacterium tuberculosis-specific host cytokine signatures in whole blood culture supernatants in the diagnosis of tuberculosis disease</i>	TO.12
12:50-13:00	Q&A session	
11:30-13:00	Parallel session Malaria vaccine studies	Hall I A
	Chairs: Kalifa Bojang and Francine Ntoumi Rapporteurs: Bourema Kouriba and Eric Achidi	
11:30-11:50	Nicola K. Viebig , EVI, Germany <i>The Malaria Vectored Vaccines Consortium (MVVC): integrating capacity building and networking in the design and conduct of clinical trials in East and West Africa</i>	MO.10
11:50-12:10	Nébié Issa Ouédraogo , CNRFP, Burkina Faso <i>Assessing chimpanzee adenovirus serotype ChAd63 neutralising antibodies prior to the implementation of a candidate malaria vaccine regimen based on viral vectors</i>	MO.11
12:10-12:30	Alfred B. Tiono , CNRFP, Burkina Faso <i>Safety and immunogenicity of heterologous prime-boost immunisation with candidate vaccines ChAd63 ME-TRAP and MVA ME-TRAP in healthy Burkinabè children aged 5-17 months</i>	MO.12
12:30-12:50	Victorine Mensah , University Cheikh Anta Diop, Senegal <i>Efficacy study of ChAd63-MVA ME-TRAP prime-boost vaccination against Plasmodium falciparum infection in healthy adults in Senegal</i>	MO.13
12:50-13:00	Thomas Egwang , Med Biotech Laboratories, Uganda <i>Maternal immunisation protects mice pups against malaria</i>	MO.14
11:30-13:00	Parallel session Cross-cutting: interactions of neglected infectious diseases (NIDs) with HIV, tuberculosis and malaria	Salon 3-4
	Chairs: Alison Elliott and Wilfred Mbacham Rapporteurs: Ayola Akim Adegnika and Seni Kouanda	
11:30-11:50	Josephine Wanyenze , MRC-UVRI, Uganda <i>HIV and schistosoma mansoni coinfections among adults in fishing communities along Lake Victoria, Uganda</i>	CO.09
11:50-12:10	Marguerite Massinga Loembé , CERMEL, Gabon <i>Detangling immune interactions between schistosomiasis and malaria in coinfecting individuals</i>	CO.10
12:10-12:30	Annemieke Geluk , LUMC, The Netherlands <i>Field evaluation of an up-converting phosphor-lateral flow assay for detection of cellular and humoral immunity against mycobacteria</i>	CO.11
12:30-12:50	Clovis Seumen , University of Yaounde I, Cameroon <i>Effect of concurrent gastrointestinal nematode infections on antimalarial total IgG in school-age children in Mfou</i>	CO.12

12:50-13:00	Q&A session	
13:00-14:00	Lunch	Hall II
13:00-14:00	Marketplace views	Hall II
14:00-16:00	Parallel session HIV/AIDS comorbidities	Hall I B-C
	Chairs: Shabbar Jaffar and Knut Fylkesnes Rapporteurs: Edwin Were and Jonathan Kayondo	
14:00-14:15	Veronica Mulenga , University Teaching Hospital, Zambia CHAPAS 3: A randomised trial comparing two-year toxicity and efficacy of stavudine vs zidovudine vs abacavir as NNRTI-based fixed dose combination antiretroviral drug regimens for starting or substituting from stavudine-based antiretroviral therapy in 478 HIV-infected children in Uganda and Zambia	HO.16
14:15-14:30	Grace Mirembe , JCRC Kampala, Uganda <i>Cardiovascular structure and function in HIV-infected children in Zambia and Uganda: CHAPAS-3 trial</i>	HO.17
14:30-14:45	Victor Musiime , JCRC Kampala, Uganda <i>Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial</i>	HO.18
14:45-15:00	Chishala Chabala , UTH, Zambia <i>Assessment of peripheral neuropathy among HIV-infected children on fixed-dose antiretroviral therapy in Zambia and Uganda: the CHAPAS-3 randomised clinical trial</i>	HO.19
15:00-15:20	Guy Bumoko , University of Kinshasa, Democratic Republic of Congo <i>Cognition abilities and daily life functioning of HIV-infected subjects under antiretroviral therapy</i>	HO.20
15:20-15:40	Seth Inzaule , KEMRI, Kenya <i>Incidence and predictors of first-line antiretroviral regimen modification in western Kenya</i>	HO.21
15:40-16:00	Ismail Mbowo , Moi University, Kenya <i>Correlates of separation among HIV-serodiscordant couples enrolled in partners PrEP study site clinic in Eldoret western Kenya</i>	HO.22
14:00-16:00	Parallel session Tuberculosis studies on diagnostics	Salon 2
	Chairs: Ali Zumla and Gerhard Walzl Rapporteurs: Nesri Padayatchi and Jean Nachega	
14:00-14:20	Klaus Reither , Swiss TPH, Switzerland <i>Evaluation of new and emerging diagnostics for childhood tuberculosis in high-burden countries: update from the TB CHILD project</i>	TO.13
14:20-14:40	Grant Theron , University of Cape Town, South Africa <i>Xpert MTB/RIF assay for the diagnosis of tuberculosis using non-sputum samples in a HIV-prevalent setting</i>	TO.14
14:40-15:00	Sokoine Kivuyo , NIMR Muhimbili, Tanzania <i>Diagnosing tuberculosis in advanced HIV infection in Africa: the role of the Xpert MTB/RIF assay</i>	TO.15

15:00-15:20	Abigail Ayorinde , MRC, The Gambia <i>Contribution of the Xpert MTB/RIF assay to the diagnosis of pulmonary tuberculosis in a West African childhood TB clinic</i>	TO.16
15:20-15:40	Willy Ssengooba , Makerere University, Uganda <i>Comparative effectiveness of Xpert MTB/RIF assay when used as add-on test to smear microscopy for diagnosis of pulmonary tuberculosis among HIV-infected Ugandan adults</i>	TO.17
15:40-16:00	Boitumelo Fanampe , University of Cape Town, South Africa <i>Development of an aptamer to a Th1 cytokine</i>	TO.18
14:00-16:00	Parallel session Pregnancy associated malaria studies	Hall I A
	Chairs: Philippe Deloron and Eusébio Macete Rapporteurs: Montserrat Blázquez Domingo and Pauline Byakika	
14:00-14:15	Raquel González , CRESIB, Spain <i>Efficacy and safety of mefloquine as malaria intermittent preventive treatment in pregnancy: results from a multicentre randomised clinical trial</i>	MO.15
14:15-14:30	Raquel González , CRESIB, Spain <i>Efficacy and safety of mefloquine as malaria intermittent preventive treatment in pregnancy in HIV-infected women receiving daily cotrimoxazole prophylaxis</i>	MO.16
14:30-14:45	Michael Ramharter , CERMEI, Gabon <i>Rich and population pharmacokinetics of mefloquine intermittent preventive treatment against malaria in pregnant women in Gabon</i>	MO.17
14:45-15:00	Feiko ter Kuile , LSTM, United Kingdom and KEMRI, Kisumu, Kenya <i>Impact of sulphadoxine-pyrimethamine resistance on the effectiveness of Intermittent Preventive Therapy for malaria in pregnancy (IPTp) in Africa: A systematic review and meta-analysis</i>	MO.18
15:00-15:20	Harry Tagbor , LSHTM, United Kingdom <i>A trial of intermittent screening and treatment as an alternative to intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria in pregnancy</i>	MO.19
15:20-15:40	Kassoum Kayentao , MRTC, University of Bamako, Mali <i>Intermittent preventive therapy for malaria in pregnancy using 2 vs. 3 more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: a systematic review</i>	MO.20
15:40-16:00	Jean Louis Ndiaye , University Cheikh Anta Diop, Senegal <i>Effectiveness of seasonal malaria chemoprevention combined with community case management for malaria in southern Senegal: a cluster-randomised trial</i>	MO.21
14:00-16:00	Parallel session Cross-cutting: ethics and good practices	Salon 3-4
	Chairs: Alioune Dieye and Wilfred Mbacham Rapporteurs: Esther Nkandu and Elizabeth Pienaar	
14:00-14:20	Lyn Horn and Mariana Kruger , Stellenbosch University, South Africa <i>Research Ethics in Africa: a resource for Research Ethics Committees</i>	CO.13

14:20-14:40	Godfrey B. Tangwa , CAMBIN, Cameroon <i>Small is beautiful: demystifying and simplifying SOPs: the model of the Ethics Review and Consultancy Committee of the Cameroon Bioethics Initiative</i>	CO.14
14:40-15:00	Martin Matu , ECSA-HC, Tanzania <i>Status of research ethics bodies in East, Central and Southern Africa Health Community region</i>	CO.15
15:00-15:20	Modest Mulenga , TDRN Ndola, Zambia <i>Engaging policy makers in clinical trials to accelerate policy formulation in sub-Saharan Africa</i>	CO.16
15:20-15:40	Mary Kasule , University of Botswana, Botswana <i>Building research capacity in Botswana: a randomised trial comparing training methodologies in the Botswana ethics training initiative</i>	CO.17
15:40-16:00	Charles N. Fokunang , University of Bamenda, Cameroon <i>Ethical implications in clinical genetic and genomic research for the emerging countries</i>	CO.18
16:00-16:30	Coffee and tea break	Hall II
16:00-16:30	Marketplace views	Hall II
16:30-17:10	Parallel session (Cont.) HIV/AIDS comorbidities	Hall I B-C
	Chairs: Shabbar Jaffar and Maria Fraga Oliveira Martins Rapporteurs: Photini Kiepiela and Jonathan Kayondo	
16:30-16:50	Suzanne Filteau , LSHTM, United Kingdom <i>Nutritional intervention to reduce early mortality in HIV-infected African adults starting antiretroviral therapy</i>	HO.23
16:50-17:10	Valérie Leroy , University of Bordeaux Segalen, France <i>Twelve-month virological response in children initiated on lopinavir containing antiretroviral therapy before 2 years of age in Abidjan, Côte d'Ivoire and Ouagadougou, Burkina Faso</i>	HO.24
16:30-17:10	Parallel session Tuberculosis drug development and drug resistance	Salon 2
	Chairs: Eleni Aklillu and Marilyn Bonnet Rapporteurs: Michelle Nderu and Pete Murphy	
16:30-16:50	Patrick Kobina Arthur , University of Ghana <i>Analysis of anti-mycobacterial compounds produced by marine endophytic fungi</i>	TO.19
16:50-17:10	Bamidele Iwalokun , NIMR, Nigeria <i>Association between leptin receptor gene (LeprglN233arg) polymorphism and tuberculosis relapse in Nigerian patients</i>	TO.20
16:30-17:10	Parallel session Pregnancy associated malaria studies	Hall I A
	Chairs: Philippe Deloron and Eusébio Macete Rapporteurs: Charles Obonyo and Eric Achidi	
16:30-16:50	José Francisco Fernandes , Albert Schweitzer Hospital, Lambaréné, Gabon <i>Fosmidomycin as an antimalarial drug: review of clinical trials</i>	MO.22

16:50-17:10	Rakiswendé Serge Yerbanga , IRSS-DRO, Burkina Faso <i>Artesunate in vivo activity on Plasmodium falciparum forms in the mosquito Anopheles coluzzii</i>	MO.23
16:30-17:10	Parallel session (Cont.) Cross-cutting: ethics and good practices Chairs: Alioune Dieye and Wilfred Mbacham Rapporteurs: Esther Nkandu and Elizabeth Pienaar	Salon 3-4
16:30-16:50	Kevin Fisher , AVAC, United States of America <i>Global implementation of good participatory practice guidelines for biomedical HIV prevention and tuberculosis research: charting progress and setting milestones</i>	CO.19
16:50-17:10	Dan Kajungu , Catholic University of Leuven, Belgium/Uganda <i>Paediatric pharmacovigilance: data mining algorithms for signal detection in phase IIIb clinical trials safety datasets from seven African countries</i>	CO.20
17:10-18:00	Marketplace views	Hall II
17:30-19:00	Satellite meeting Global TB Vaccine Partnership	Salon 3-4
17:30-20:30	Satellite meeting ESSENCE on Health Research initiative, members' dinner meeting <i>By invitation only</i>	Salon 2

Wednesday 2 July 2014

08:00-09:00	Registration	Foyer, Conference centre
08:00-09:30	Parallel session EDCTP and CAAST-NET Plus: Building bridges	Hall I B-C
	Chairs: Ole Olesen and Daan du Toit Rapporteurs: Ana Lúcia Cardoso, Lara Pandya and Katharina Kuss	
08:00-09:30	Parallel session EDCTP Africa mapping project: current state of health research on poverty-related and neglected infectious diseases in sub-Saharan Africa	Hall I A
	Chairs: Michael Makanga and Gabrielle Breugelmans Rapporteurs: Michelle Nderu and Hager Bassyouni	
09:40-11:00	Parallel session HIV/AIDS treatment guidelines and disease progression	Hall I B-C
	Chairs: Gita Ramjee and Pontiano Kaleebu Rapporteurs: Catherine Orrell and Hager Bassyouni	
09:40-10:00	Vincent Tukei , BIPAI, Uganda <i>Using WHO 2010 dosing guidelines, efavirenz levels remain slightly lower and highly variable in Ugandan and Zambian children weighing 10-20kg</i>	HO.25
10:00-10:20	Gaone Retshabile , BHP, Botswana <i>Sub-optimal CD4 T cell recovery in HIV-1 subtype C patients on antiretroviral therapy: a search for predictive biomarkers and baseline characteristics</i>	HO.26
10:20-10:40	Deogratius Ssemwanga , MRC-UVRI AIDS, Uganda <i>HIV-1 multiple infection and disease progression in a cohort of female sex workers in Uganda</i>	HO.27
10:40-11:00	Thato Iketleng , BHP, Botswana <i>Plasma cytokine levels in chronic asymptomatic HIV-1 subtype C infection as an indicator of disease progression in Botswana: a retrospective case control study</i>	HO.28
09:40-11:00	Parallel session Tuberculosis immunology	Salon 2
	Chairs: Beate Kampmann and Martin Ota Rapporteur: Michelle Nderu and Jean Nachega	
09:40-10:00	Veronique Penlap Beng , University of Yaounde 1, Cameroon <i>Insight of the genetic variability of Mycobacterium tuberculosis complex and drug resistance in Yaounde, Cameroon</i>	TO.21
10:00-10:20	Fredrick Lutwama , Makerere University, Uganda <i>Distinct T cell responses when Bacillus Calmette Guerin is delayed from birth to six weeks of age in Ugandan infants</i>	TO.22
10:20-10:40	Niaina Rakotosamimanana , Institut Pasteur de Madagascar <i>Peripheral blood TNF-alpha-dependent apoptotic genes expression and white blood cell count to characterise the tuberculosis clinical status of individuals in a high-burden setting</i>	TO.23

Wednesday 2 July 2014

10:40-11:00	Q&A session	
09:40-11:00	Parallel session Malaria coinfections, drug resistance and modeling	Hall I A
	Chairs: Philippe Deloron and Maria Fraga Oliveira Martins Rapporteurs: Bourema Kouriba and Kamija Phiri	
09:40-10:00	Ghyslain Mombo-Ngoma , CERMEL, Gabon <i>Efficacy of mefloquine intermittent preventive treatment in pregnancy against Schistosoma haematobium infection in Gabon: a randomised controlled clinical trial</i>	MO.24
10:00-10:20	Peter Kimbowa , Save A Life Foundation, Uganda <i>Effect of antiretroviral therapy on malaria parasitaemia and clinical episodes among HIV-infected adults in rural Uganda, 2009: a prospective population-based cohort study</i>	MO.25
10:20-10:40	Philippe Guerin , WWARN <i>Investigation of sampling designs for accurate estimation of parasite clearance in the context of artemisinin resistance</i>	MO.26
10:40-11:00	Issaka Sagara , MRTC, University of Bamako, Mali <i>Modelling recurrent events: comparison of statistical models with continuous and discontinuous risk intervals on repeated malaria episodes data</i>	MO.27
09:40-11:00	Parallel session Cross-cutting: training and networking activities	Salon 3-4
	Chairs: Alioune Dieye and Dawit Wolday Rapporteurs: Lucinda Manda-Taylor and Elizabeth Pienaar	
09:40-10:00	Photini Kiepiela , MRC (HPRU), South Africa <i>Experiences in using e-learning to improve the capacity of African scientists in South Africa</i>	CO.21
10:00-10:20	Peninah Menza , DNDi, Kenya <i>EACCR: coordination of the malaria node activities</i>	CO.22
10:20-10:40	Dembo Kanteh , MRC, The Gambia <i>Towards strengthening the West African network of excellence for tuberculosis, HIV/AIDS and malaria: WANETAM Plus</i>	CO.23
10:40-11:00	Hulda Swai , CSIR, South Africa <i>The Pan-African Centre of Excellence in Nanomedicine: research and training on poverty-related diseases</i>	CO.24
11:00-11:30	Coffee and tea break	Hall II
11:00-11:30	Marketplace views	Hall II
11:30-13:00	Plenary session IV EDCTP partners' Session	Hall I B-C
	Chairs: Marie-Louise Newell and Ole Olesen Rapporteur: Karin Fischer-Buder	
13:00-14:00	Lunch	Hall II
13:00-14:00	Marketplace views	Hall II

Wednesday 2 July 2014

14:00-15:30	Parallel session HIV/AIDS coinfections	Hall I B-C
	Chairs: Souleymane Mboup and Pontiano Kaleebu Rapporteurs: Edwin Were and Jonathan Kayondo	
14:00-14:15	Mary Mwaura , ICHR, Kenya <i>The need for multipurpose prevention technologies targeting HIV and common reproductive tract infections: data from the Microbicide Safety Biomarkers study</i>	HO.29
14:15-14:30	Ivete Meque , UCM, Mozambique <i>Prevalence, incidence and determinants of Herpes simplex virus type 2 infection among HIV-seronegative women at high risk of HIV infection: a prospective study in Beira, Mozambique</i>	HO.30
14:30-14:45	Motswedi Anderson , BHP, Botswana <i>Molecular characterisation of hepatitis B virus in HIV-coinfected patients in Botswana</i>	HO.31
14:45-15:00	Lerato Magosi , BHP, Botswana <i>Toll-like receptor 4 polymorphisms in Botswana and impact on susceptibility to Kaposi's sarcoma in HIV-1 subtype C-infected patients</i>	HO.32
15:00-15:15	Bernard Ngowi , NIMR, Tanzania <i>Screening for cryptococcal meningitis in patients with advanced HIV infection: the role of serum cryptococcal antigen test</i>	HO.33
15:15-15:30	Q&A session	
14:00-15:30	Parallel session Tuberculosis	Salon 2
	Chairs: Tumani Corrah and Beate Kampmann Rapporteurs: Hager Bassyouni and Pete Murphy	
14:00-14:20	John Hongo , KEMRI-CDC Kenya <i>Experiences in using real-time electronic and paper-based data capturing methods among studies conducted by the tuberculosis research branch, KEMRI-CDC programme in western Kenya</i>	TO.24
14:20-14:40	Barbara Burmen , KEMRI-CDC Kenya <i>Prevalence of non-tuberculous mycobacteria in HIV-infected patients, Nyanza province, Kenya</i>	TO.25
14:40-15:00	Peter Onyango , KEMRI-CDC Kenya <i>Experiences in implementing a study comparing post-mortem and verbal autopsy for measuring tuberculosis mortality in Kenya</i>	TO.26
15:00-15:20	Toyin Togun , MRC, The Gambia <i>Assessing responses to tuberculosis treatment using a simple clinical scoring system: data from the tuberculosis case-contact cohort in The Gambia</i>	TO.27
15:20-15:40	Tutty Isatou Faal-Jawara , MRC, The Gambia <i>Sequencing of variable T cell epitopes of Mycobacterium tuberculosis from confirmed tuberculosis cases in The Gambia</i>	TO.28

14:00-15:30	Parallel session Malaria immunology and diagnostics	Hall I A
	Chairs: Dawit Wolday and Wilfred Mbacham Rapporteurs: Eric Achidi and Bourema Kouriba	
14:00-14:15	Alphonse Ouédraogo , CNRFP, Burkina Faso <i>Pyrogenic threshold for malaria disease definition in an endemic area of Burkina Faso</i>	MO.28
14:15-14:30	Amidou Diarra , CNRFP, Burkina Faso <i>Seasonal variation and clinical protection of antibodies against a panel of malaria antigens in children under five years of age in Burkina Faso</i>	MO.29
14:30-14:45	Guillaume S. Sanou , CNRFP, Burkina Faso <i>Assessing regulatory T cells in children with severe malaria in Burkina Faso</i>	MO.30
14:45-15:00	Larissa Aurore Tobol Bouyoukou Hounkpatin , CERMEL, Gabon <i>Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura</i>	MO.31
15:00-15:15	Maria Rebelo , CERMEL, Gabon <i>Haemozoin detection assay: a novel ex vivo assay to detect antimalarial drug resistance</i>	MO.32
15:15-15:30	Q&A session	
14:00-15:30	Parallel session Cross-cutting	Salon 3-4
	Chairs: Abraham Aseffa and Alioune Dieye Rapporteurs: Christine Wasunna and Farirai Mutenherwa	
14:00-14:15	Christine Wasunna , KEMRI, Kenya <i>Establishment of a centralised clinical trials register in Kenya: a model for knowledge sharing and exchange across two institutions</i>	CO.25
14:15-14:30	Joseph Gaie , University of Botswana <i>Opportunities and challenges: sharing experiences of IRB/REC members in a developing country</i>	CO.26
14:30-14:45	Kolawole Oyedeji , NIMR, Nigeria <i>Capacity building and evaluation of post training operational capacities of three ethics review committees in Nigeria: best practice</i>	CO.27
14:45-15:00	Galekgatlhe Bailey Balekang , Health Research Division, Ministry of Health, Botswana <i>Challenges of establishing and running Community Advisory Boards in Botswana</i>	CO.28
15:00-15:15	Muhammed Afolabi , MRC, The Gambia <i>Digitised audio questionnaire for assessment of informed consent comprehension in a low literacy African research population: development and psychometric evaluation</i>	CO.29
15:15-15:30	Palmer Netongo , ISHReCA, Cameroon <i>Towards an ISHReCA manifesto to guide researchers as they engage in health research partnerships</i>	CO.30
15:30-16:00	Coffee and tea break	Hall II
15:30-16:00	Marketplace views	Hall II

16:00-17:15	Plenary session V Summary and closing remarks	Hall I B-C
	Chairs: Michael Makanga and Tumani Corrah	
16:00-16:30	Karin Fischer-Buder , Chief rapporteur <i>Report back from the parallel sessions focusing on summary and ideas for future strategy consideration</i>	
16:30-16:45	Prof. Charles Mgone , EDCTP Executive Director <i>Closing remarks from EDCTP</i>	
16:45-17:00	Dr Gianpietro Van de Goor , DG Research and Innovation, European Commission <i>Closing remarks from the European Commission</i>	
17:00-17:15	Dr Joachim Klein , Bundesministerium für Bildung und Forschung, Germany <i>Closing remarks from the German Government</i>	

Thursday 3 July 2014

09:00-17:00	EDCTP Stakeholder Meeting on Capacity Development	Hall I A
	<i>By invitation only</i>	